These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10754723)

  • 1. PDA comments on draft guidance for industry on changes to an approved NDA or ANDA. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1999; 53(5):264-72. PubMed ID: 10754723
    [No Abstract]   [Full Text] [Related]  

  • 2. Some further comments on aseptic processing guidance, or the fool on the hill: Parenteral Drug Association.
    Agalloco J
    PDA J Pharm Sci Technol; 2003; 57(5):324-30. PubMed ID: 14677624
    [No Abstract]   [Full Text] [Related]  

  • 3. PDA response. FDA advance notice of proposed rulemaking on electronic identification/signatures. Parenteral Drug Association.
    J Parenter Sci Technol; 1993; 47(1):4-8. PubMed ID: 8445499
    [No Abstract]   [Full Text] [Related]  

  • 4. PDA comments on draft guidance for industry, ANDAs: blend uniformity. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 2000; 54(1):2-5. PubMed ID: 10778301
    [No Abstract]   [Full Text] [Related]  

  • 5. PDA comments: SUPAC-IR, ICH Q1C, FDA draft guideline. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1995; 49(4):152-6. PubMed ID: 7552232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDA comments on proposed rule: supplements and other changes to an approved application. Parenteral Drug Applications.
    PDA J Pharm Sci Technol; 1999; 53(5):273-6. PubMed ID: 10754724
    [No Abstract]   [Full Text] [Related]  

  • 7. PDA comments: active pharmaceutical ingredients/guidance. PDA Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1997; 51(3):137-8. PubMed ID: 9203828
    [No Abstract]   [Full Text] [Related]  

  • 8. PDA comments. "Review of general biologics licensing regulations". Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1995; 49(2):59-61. PubMed ID: 7780745
    [No Abstract]   [Full Text] [Related]  

  • 9. PDA comments on USP in-process revision <1116> microbiological evaluation of clean rooms and other controlled environments. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1995; 49(6):264-6. PubMed ID: 8581456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDA comments: PIC draft recommendations on the inspection of isolator technology. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1999; 53(3):141-7. PubMed ID: 10754704
    [No Abstract]   [Full Text] [Related]  

  • 11. PDA comments: PIC-S active pharmaceutical ingredients. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1998; 52(5):234-5. PubMed ID: 9846072
    [No Abstract]   [Full Text] [Related]  

  • 12. PDA presentation at FDA Open Conference on Sterile Drug Manufacturing. Parenteral Drug Association.
    J Pharm Sci Technol; 1994; 48(1):4-6. PubMed ID: 8004417
    [No Abstract]   [Full Text] [Related]  

  • 13. Continuous cell lines as substrates for biologicals. Draft position paper. Pharmaceutical Manufacturer's Association.
    Dev Biol Stand; 1989; 70():285-7. PubMed ID: 2759355
    [No Abstract]   [Full Text] [Related]  

  • 14. The parenteral drug industry: recent findings.
    Fry EM
    J Parenter Sci Technol; 1982; 36(2):55-8. PubMed ID: 7077464
    [No Abstract]   [Full Text] [Related]  

  • 15. Current regulatory issues regarding parenteral inspections.
    Avallone H
    J Parenter Sci Technol; 1989; 43(1):3-7. PubMed ID: 2926605
    [No Abstract]   [Full Text] [Related]  

  • 16. International Conference on Harmonisation; S10 Photosafety Evaluation of Pharmaceuticals; guidance for industry; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2015 Jan; 80(17):4282-3. PubMed ID: 25730921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of guidance modules by the PDA to extend and/or eliminate periodic validation: a proposal to PDA Scientific Advisory Board.
    Korczynski MS
    PDA J Pharm Sci Technol; 2003; 57(4):245-8. PubMed ID: 14558698
    [No Abstract]   [Full Text] [Related]  

  • 18. Current good manufacturing practice: proposed revision of certain requirements for finished pharmaceuticals; proposed rule, May 3, 1996 (61 FR 20103), [Docket No. 95N-0362]. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1996; 50(6):346-51. PubMed ID: 9038078
    [No Abstract]   [Full Text] [Related]  

  • 19. Comments about vitamins, nutraceuticals, and dietary enzymes.
    Henderson TR
    J Am Vet Med Assoc; 1995 Jul; 207(1):31. PubMed ID: 7601686
    [No Abstract]   [Full Text] [Related]  

  • 20. PDA response. "Guideline for submitting documentation for sterilization process validation in applications for human and veterinary drug products". Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1995; 49(2):62-6. PubMed ID: 7780746
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.